2 unknown, 1 terminated. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 2, Terminated 1 |
| Phase 1 | 2 | Terminated 1, Unknown 1 |
Follow Phoenicis Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene PTW-002 10 mg/g gel, Placebo - Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Unknown | Phoenicis Therapeutics | 8 | 2023-04-30 | 2023-03-31 |
| Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa PTM-001, Placebo - Hidradenitis Suppurativa | Phase 2 | Unknown | Phoenicis Therapeutics | 50 | 2022-05-05 | 2022-10-26 |
| A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene QR-313, Placebo - Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant | Phase 1 / Phase 2 | Terminated | Phoenicis Therapeutics | 2 | 2018-07-02 | 2021-08-25 |
Epidermolysis Bullosa Dystrophica (2) · Dermatitis (1) · Epidermolysis Bullosa (1) · Hidradenitis Suppurativa (1)
Gels (1)
United States (3) · France (1) · Spain (1)
Hal Landy, MD (1)
2017 (1)